Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer

This is a 2x2 factorial randomized, multicenter, international, open phase III trial. The primary objective is to evaluate the benefit of acetylsalicylic acid and atorvastatin on overall survival (OS) (main endpoint) for patients with castrate-resistant prostate cancer starting first line treatment for CRPC

Trial Details

NCT ID
NCT03819101
Phase
PHASE3
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Acetylsalicylic acid
  • Atorvastatin
Locations (sample)
  • Olomouc, Czechia|49.59552,17.25175
  • Villejuif, Val de Marne, France|48.7939,2.35992
  • Besançon, France|47.24878,6.01815
  • Cergy-Pontoise, France|49.03894,2.07805
  • Clermont-Ferrand, France|45.77969,3.08682

Key Eligibility Criteria

  • Histologically confirmed adenocarcinoma of the prostate and no curative local therapy considered possible
  • Age ≥ 18 years, life expectancy of at least 6 months
  • CRPC defined as tumor progression (PSA increase on at least 2 separate values separated by at least 1 week or progression on imaging) while on Andr…
  • Presence (M1) or absence (M0) of metastases on imaging

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →